Annexon, Inc. (ANNX): Entry into a Material Definitive Agreement
Annexon, Inc. (ANNX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 d113783dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “ Agreement ”) dated as of July 30, 2026 (the “ Effective Date ”) among OX
How this was made
The 30-second read
Why it matters
A new secured term-loan facility with multiple draw periods can change the company’s liquidity profile and credit risk, influencing equity valuation through discount rates and perceived survival probability.
Market read
Traders can update models for Annexon’s leverage and runway based on the facility size and draw mechanics, pending full terms (pricing, covenants, proceeds).
What to watch
Key drivers are missing from the excerpt: interest rate, maturity, collateral package, financial covenants, and whether proceeds reduce dilution or fund specific clinical milestones.
Background
The filing is an SEC Form 8-K for Annexon, Inc. reporting entry into a material definitive agreement and creation of a direct financial obligation.
Ticker impact
Annexon entered a material definitive loan and security agreement, including a $50M initial term loan and additional draw tranches.
Likely modest, two-sided reaction unless the final economics (rates, covenants, use of proceeds) materially change perceived solvency or dilution risk.
This is a primary SEC filing with concrete facility size and draw structure, but the excerpt does not include pricing, covenants, or proceeds details that would determine magnitude of credit and equity impact.
Market effects
Secured financing terms can be read across to biotech/small-cap credit conditions, but no sector-wide policy or peer-specific catalyst is provided here.
No direct regional macro linkage beyond general US credit markets.
Limited, as the facility is US-based and company-specific with no cross-border transaction details in the excerpt.
Counterpoint
The facility may extend runway and reduce near-term refinancing risk, which can be equity-supportive if proceeds fund operations or trials.
Key entities
- public_companyAnnexon, Inc.
Borrower under the loan and security agreement disclosed in the 8-K.
- lender_collateral_agentOxford Finance LLC
Collateral agent and lender party in the agreement.
- lenderOxford Finance Credit Fund IV LP
Lender under the agreement.
